Skip to main content

EGFR mutations

Test Your Knowledge
08/03/2021
The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.
The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.
The combination of...
08/03/2021
Oncology
News
07/22/2021
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in combination with chemotherapy were studied for safety variables in patients with advanced non-small-cell lung cancer (NSCLC) and sensitive EGFR mutations.
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in combination with chemotherapy were studied for safety variables in patients with advanced non-small-cell lung cancer (NSCLC) and sensitive EGFR mutations.
Epidermal growth factor...
07/22/2021
Oncology
Research Reports
05/06/2016
Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...
Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...
...
05/06/2016
Journal of Clinical Pathways